Blog
RSS FeedPosted by Michael Wonder on 28 Aug 2021
Merck’s Keytruda (pembrolizumab) receives two new approvals in Japan
26 August 2021 - Keytruda now approved for the treatment of patients with PD-L1 positive, hormone receptor negative and HER2 negative, ...
Posted by Michael Wonder on 26 Aug 2021
Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type 2 diabetes
26 August 2021 - Approval marks an important transformation in the treatment of more than 13 million people suffering from ...
Posted by Michael Wonder on 25 Aug 2021
Ono and Takeda receive an approval for Opdivo (nivolumab) and Cabometyx (cabozantinib) combination therapy in Japan for treatment of unresectable or metastatic renal cell carcinoma
25 August 2021 - Ono Pharmaceutical and Takeda today announced that the companies have received an approval for combination therapy of ...
Posted by Michael Wonder on 18 Aug 2021
AmoyDx Pan lung cancer PCR panel receives MHLW approval as companion diagnostic for Tepmetko (tepotinib)
17 August 2021 - Riken Genesis, Amoy Diagnostics and Precision Medicine Asia today announced that the Ministry of Health, Labour ...
Posted by Michael Wonder on 09 Aug 2021
Japan drug maker Shionogi to seek approval for oral COVID-19 drug
6 August 2021 - Pharmaceutical firm Shionogi plans to seek state approval for its oral coronavirus drug by the end ...
Posted by Michael Wonder on 20 Jul 2021
Japan becomes first country to approve Regeneron antibody cocktail (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
20 July 2021 - Regeneron Pharmaceuticals today announced that Japan's Ministry of Health, Labour and Welfare has approved Regeneron's casirivimab and ...
Posted by Michael Wonder on 04 Jul 2021
Solasia announces submission of new drug application for anti-cancer drug darinaparsin for peripheral T-cell lymphoma in Japan
30 June 2021 - New drug application filed in Japan ahead of anywhere else in the world. ...
Posted by Michael Wonder on 25 Jun 2021
Vericiguat approved in Japan to treat patients with chronic heart failure
23 June 2021 - Heart failure affects approximately 1.2 million people in Japan. ...
Posted by Michael Wonder on 24 Jun 2021
Evrysdi approved in Japan for the treatment of spinal muscular atrophy
23 June 2021 - 48th country that approved Evrysdi. ...
Posted by Michael Wonder on 24 Jun 2021
Teva announces Ministry of Health, Labour and Welfare approves Ajovy (fremanezumab) injection in Japan for the preventive treatment of migraine in adults
23 June 2021 - Ajovy developed by Otsuka in Japan through exclusive license agreement. ...
Posted by Michael Wonder on 24 Jun 2021
Anticancer agent Tazverik 200 mg tablets (tazemetostat hydrobromide) approved in Japan for EZH2 gene mutation positive follicular lymphoma
23 June 2021 - Eisai announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor Tazverik ...
Posted by Michael Wonder on 11 Jun 2021
Delytact oncolytic virus G47∆ approved in Japan for treatment of patients with malignant glioma
10 June 2021 - First oncolytic virus ever approved for treatment of malignant glioma or any primary brain cancer. ...
Posted by Michael Wonder on 31 May 2021
Marketing approval received in Japan for Ninlaro as a maintenance therapy after first-line treatment for multiple myeloma without prior stem cell transplantation
27 May 2021 - Takeda today announced that it has received approval from the Japanese Ministry of Health, Labour and ...
Posted by Michael Wonder on 24 May 2021
Japan issues final approval for Moderna and AstraZeneca vaccines
21 May 2021 - Health minister Norihisa Tamura gave his final approval Friday for emergency use of two more COVID-19 ...
Posted by Michael Wonder on 14 May 2021
Japan’s Ministry of Health, Labour and Welfare grants priority review for enfortumab vedotin new drug application
14 May 2021 - New drug application, submitted in March, is for locally advanced or metastatic urothelial cancer that has ...